These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24184129)

  • 1. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.
    Komatsu TE; Pikis A; Naeger LK; Harrington PR
    Antiviral Res; 2014 Jan; 101():12-25. PubMed ID: 24184129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
    Campos AB; Ribeiro J; Boutolleau D; Sousa H
    Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
    J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
    Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
    Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
    Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
    Baldanti F; Lurain N; Gerna G
    Hum Immunol; 2004 May; 65(5):403-9. PubMed ID: 15172438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
    Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
    J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
    Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
    Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.
    Chou S; Boivin G; Ives J; Elston R
    J Infect Dis; 2014 Apr; 209(8):1219-26. PubMed ID: 24273181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
    Baradhi KM; Aure RL; El-Amm JM
    Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection.
    Campanini G; Zavattoni M; Cristina E; Gazzolo D; Stronati M; Baldanti F
    J Clin Virol; 2012 May; 54(1):86-8. PubMed ID: 22381918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.
    Bachmann R; Hamprecht K; Lange J; Ladurner R; Nadalin S; Jahn G; Königsrainer A; Heininger A
    Infection; 2013 Aug; 41(4):875-9. PubMed ID: 23546999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of resistance-associated mutations in UL54 and UL97 genes of circulating cytomegalovirus strains isolated in a medical center in Taiwan.
    Shao PL; Lu MY; Liau YJ; Kao CL; Chang SY; Huang LM
    J Formos Med Assoc; 2012 Aug; 111(8):456-60. PubMed ID: 22939665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
    Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
    Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
    Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene.
    Martin M; Goyette N; Boivin G
    J Clin Virol; 2010 Dec; 49(4):296-8. PubMed ID: 20843736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
    Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
    J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of drug-resistant human cytomegalovirus].
    Murayama T
    Nihon Rinsho; 2006 Mar; 64 Suppl 3():508-11. PubMed ID: 16615525
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
    Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
    Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
    Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
    Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.